Oramed Pharmaceuticals (ORMP) Share-based Compensation (2010 - 2026)

Oramed Pharmaceuticals has reported Share-based Compensation for 17 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 20.69% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (up 11.94% YoY), and the FY2025 full-year result was $6.0 million, up 47.84% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.7 million, down from $2.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $4.2 million in Q4 2023, with the low at -$8.9 million in Q4 2022.
• Historically, Share-based Compensation has averaged $942058.8 across 5 years, with a median of $1.3 million in 2024.
• Annual changes were most pronounced in 2023 — Share-based Compensation slumped 165.05% — and 2024, when it surged 647.98%.
• Oramed Pharmaceuticals' Share-based Compensation stood at -$8.9 million in 2022, then jumped by 147.02% to $4.2 million in 2023, then plunged by 70.76% to $1.2 million in 2024, then surged by 85.84% to $2.3 million in 2025, then dropped by 23.99% to $1.7 million in 2026.
• The last three Share-based Compensation figures came in at $1.7 million (Q1 2026), $2.3 million (Q4 2025), and $719000.0 (Q3 2025), per Business Quant data.